Role of agonistic autoantibodies to the angiotensin II type 1 receptor (AT1-AA) in pathogenesis of preeclampsia

Abstract

Preeclampsia(PE) is the most prevalent complication during pregnancy and constitutes a significant cause of morbidity and mortality among pregnant women and their fetuses. Recent studies have demonstrated elevated levels of angiotensin II type 1 receptor autoantibodies (AT1-AA) in patients diagnosed with PE. These autoantibodies can mimic the physiological effects of angiotensin II by engaging with the AT1 receptor, thereby instigating inflammatory responses and vasoconstriction, which contribute to the clinical manifestations of PE. Although the precise pathogenesis of PE remains unclear, it is influenced by a multitude of factors. This paper aims to provide a comprehensive overview of the relationship between PE and AT1-AA, along with an analysis of the pathophysiological effects and signaling pathways related to these autoantibodies.

Keywords

Preeclampsia / AT1-AA / Vascular inflammation

References

[1] E. Dimitriadis, D.L. Rolnik, W. Zhou, G. Estrada-Gutierrez, K. Koga, R. Francisco, C. Whitehead, J. Hyett, F. da Silva Costa, K. Nicolaides, E. Menkhorst, Pre- eclampsia, Nat. Rev. Dis. Prim. 9 (2023) 8.

[2] B. Mol, C.T. Roberts, S. Thangaratinam, L.A. Magee, C. de Groot, G.J. Hofmeyr, Pre-eclampsia, Lancet 387 (2016) 999-1011.

[3] Y. Yang, I. Le Ray, J. Zhu, J. Zhang, J. Hua, M. Reilly, Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China, JAMA Netw. Open 4 (2021) e218401.

[4] M.K. Jena, N.R. Sharma, M. Petitt, D. Maulik, N.R. Nayak, Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta, Biomolecules 10 (2020) 953.

[5] E. Bartsch, K.E. Medcalf, A.L. Park, J.G. Ray, Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies, BMJ 353 (2016) i1753.

[6] S. Lisonkova, K.S. Joseph, Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease, Am. J. Obstet. Gynecol. 209 (2013) 544. e1-544. e12.

[7] M. Mustary, Ansariadi, A. Syam, S. Riskiyani, K.A. Erika, A.I. Moedjiono, M. Lubis, Preeclampsia: Etiology, Pathophysiology, Risk Factors, Impact and Prevention: A Narrative Review, Iran. J. Public Health 53 (2024) 2392-2403.

[8] M. Yang, M. Wang, N. Li, Advances in pathogenesis of preeclampsia, Arch. Gynecol. Obstet. 309 (2024) 1815-1823.

[9] M. Sircar, R. Thadhani, S.A. Karumanchi, Pathogenesis of preeclampsia, Curr. Opin. Nephrol. Hypertens. 24 (2015) 131-138.

[10] F.J. Valenzuela, A. Pérez-Sepúlveda, M.J. Torres, P. Correa, G.M. Repetto, S.E. Illanes, Pathogenesis of preeclampsia: the genetic component, J. Pregnancy 2012 (2012) 632732.

[11] N. Campbell, B. LaMarca,M.W. Cunningham Jr., The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia, Curr. Pharm. Biotechnol. 19 (2018) 781-785.

[12] B. LaMarca, K. Wallace, J. Granger, Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia, Curr. Opin. Pharm. 11 (2011) 175-179.

[13] F. Liu, L. Yang, Y. Zheng, W. Zhang, J. Zhi, Effects and molecular mechanisms of AT1-AA in retinopathy of preeclampsia, Acta Biochim Biophys. Sin. (Shanghai) 51 (2019) 51-58.

[14] C.A. Hubel, G. Wallukat, M. Wolf, F. Herse, A. Rajakumar, J.M. Roberts, N. Markovic, R. Thadhani, F.C. Luft, R. Dechend, Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia, Hypertension 49 (2007) 612-617.

[15] J. Bian, X. Yin, L. Hao, Pregnant female mice with positive autoantibodies to angiotensin II type 1 receptors showed gestational hypertension like symptoms, J. Cap. Med. Univ. 40 (02) (2019) 257-262.

[16] S. Wei, X. Feng, Z. Yi, Exploration of changes in blood AT1-AA and tTG levels in elderly preeclampsia pregnant women and their predictive value for pregnancy outcomes, Labeling Immunoass. Clin. Pract. 30 (09) (2023) 1500-1504.

[17] U.M. Ashraf, D.L. Hall, N. Campbell, J.P. Waller, A.Z. Rawls, D. Solise, K. Cockrell, G.L. Bidwell, 3rd, D.G. Romero, N.B. Ojeda, B. LaMarca, B.T. Alexander, Inhibition of the AT(1)R agonistic autoantibody in a rat model of preeclampsia improves fetal growth in late gestation, Am. J. Physiol. Regul. Integr. Comp. Physiol. 323 (2022) R670-R681.

[18] A.C. Harmon, D.C. Cornelius, L.M. Amaral, J.L. Faulkner, M.W. Cunningham Jr, K. Wallace, B. LaMarca, The role of inflammation in the pathology of pre-eclampsia, Clin. Sci. (Lond. ) 130 (2016) 409-419.

[19] J.W. Duncan, D. Azubuike, G.W. Booz, B. Fisher, J.M. Williams, F. Fan, T. Ibrahim, B. LaMarca,M.W. Cunningham Jr., Angiotensin II type 1 receptor auto-antibody blockade improves cerebral blood flow autoregulation and hypertension in a preclinical model of preeclampsia, Hypertens. Pregnancy 39 (2020) 451-460.

[20] B. LaMarca, M.R. Parrish, K. Wallace, Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia, Gend. Med 9 (2012) 139-146.

[21] F.T. Spradley, A.C. Palei, J.P. Granger, Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms, Am. J. Physiol. Regul. Integr. Comp. Physiol. 309 (2015) R1326-R1343.

[22] G. Musso, F. Saba, M. Cassader, E. Paschetta, F. De Michieli, S. Pinach, L. Framarin, M. Berrutti, N. Leone, R. Parente, M.T. Ayoubi Khajekini, A. Zarovska, R. Gambino, Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro- Inflammatory Cell Activation, Am. J. Gastroenterol. 114 (2019) 607-619.

[23] H. Okada, Y. Watanabe, T. Kobayashi, T. Kikuta, Y. Kanno, H. Suzuki, Angiotensin II type 1 and type 2 receptors reciprocally modulate pro-inflammatory/ pro- fibrotic reactions in activated splenic lymphocytes, Am. J. Nephrol. 24 (2004) 322-329.

[24] B. Lamarca, The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia, Minerva Ginecol. 62 (2010) 105-120.

[25] M.W. Cunningham, Jr, V.R. Vaka, K. McMaster, T. Ibrahim, D.C. Cornelius, L. Amaral, N. Campbell, G. Wallukat, S. McDuffy, N. Usry, R. Dechend, B. LaMarca, Renal natural killer cell activation and mitochondrial oxidative stress; new mechanisms in AT1-AA mediated hypertensive pregnancy, Pregnancy Hypertens. 15 (2019) 72-77.

[26] M. Hu, J. Li, P.N. Baker, C. Tong, Revisiting preeclampsia: a metabolic disorder of the placenta, FEBS J. 289 (2022) 336-354.

[27] S. Aggarwal, A. Makris, A. Hennessy, Linking the old and new - do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia, Hypertens. Pregnancy 34 (2015) 369-382.

[28] Y. Li, Y. Xu, Y. Wang, Research progress on premature aging of placenta caused by oxidative stress in preeclampsia, J. Southeast Univ. ( Med. Ed. ) 42 (06) (2023) 950-954.

[29] R. Zhai, Y. Liu, J. Tong, Y. Yu, L. Yang, Y. Gu, J. Niu, Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies, Front Pharm. 13 (2022) 826792.

[30] Y. Li, Y. Long, X. Zhi, H. Hao, X. Wang, H. Liu, L. Wang, miR-339-3p promotes AT1-AA-induced vascular inflammation by upregulating NFATc3 protein expression in vascular smooth muscle cells, Acta Biochim Biophys. Sin. (Shanghai) 55 (2023) 295-303.

[31] Y. Hojo, U. Ikeda, Y. Maeda, M. Takahashi, T. Takizawa, M. Okada, H. Funayama, K. Shimada, Interaction between human monocytes and vascular smooth muscle cells induces vascular endothelial growth factor expression, Atherosclerosis 150 (2000) 63-70.

[32] R.A. Bobadilla, R. van Bree, L. Vercruysse, R. Pijnenborg, J. Verhaeghe, Placental effects of systemic tumour necrosis factor-α in an animal model of gestational diabetes mellitus, Placenta 31 (2010) 1057-1063.

[33] Q. Zhou, X. Xue, Expression and clinical significance of FGL2 and TNF - α in placental tissue of preeclampsia, Jt. Logist. Mil. Med. 37 (10) (2023) 849-852.

[34] G. Bobek, L. Surmon, K.M. Mirabito, A. Makris, A. Hennessy, Placental Regulation of Inflammation and Hypoxia after TNF-α Infusion in Mice, Am. J. Reprod. Immunol. 74 (2015) 407-418.

[35] S. Bu, Y. Wang, S. Sun, Y. Zheng, Z. Jin, J. Zhi, Role and mechanism of AT1-AA in the pathogenesis of HELLP syndrome, Sci. Rep. 8 (2018) 279.

[36] M.W. Cunningham, Jr, J. Castillo, T. Ibrahim, D.C. Cornelius, N. Campbell, L. Amaral, V.R. Vaka, N. Usry, J.M. Williams, B. LaMarca, AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats, Hypertension 71 (2018) 886-893.

[37] A.H. Siddiqui, R.A. Irani, W. Zhang, W. Wang, S.C. Blackwell, R.E. Kellems, Y. Xia,Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia, Hypertension 61 (2013) 472-479.

[38] F. Herse, B. LaMarca, Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension, Am. J. Reprod. Immunol. 69 (2013) 413-418.

[39] G.B. Morrow, N.J. Mutch, Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1), Semin Thromb. Hemost. 49 (2023) 305-313.

[40] A. Gils, P.J. Declerck, Plasminogen activator inhibitor-1, Curr. Med Chem. 11 (2004) 2323-2334.

[41] Y. Yu, L. Zhang, G. Xu, Z. Wu, Q. Li, Y. Gu, J. Niu, Angiotensin II Type I Receptor Agonistic Autoantibody Induces Podocyte Injury via Activation of the TRPC6- Calcium/Calcineurin Pathway in Pre-Eclampsia, Kidney Blood Press Res 43 (2018) 1666-1676.

[42] J. Shen, N. Hu, Z. Wang, L. Yang, R. Chen, L. Zhang, X. Wang, Ghrelin alleviates placental dysfunction by down-regulating NF-κB phosphorylation in LPS-induced rat model of preeclampsia, Eur. J. Pharm. 972 (2024) 176569.

[43] X. Zhang, Y. Hu, Z. Zhang, X. Zhang, L. Liang, X. Cui, Y. Wu, F. Hu, X. Wu, Inhibition of TMUB1 blocks apoptosis and NF-κB pathway-mediated inflammation in recurrent spontaneous abortion, Immun. Inflamm. Dis. 11 (2023) e879.

[44] R. Lan, Y. Yang, J. Song, L. Wang, H. Gong, Fas regulates the apoptosis and migration of trophoblast cells by targeting NF-κB, Exp. Ther. Med 22 (2021) 1055.

[45] A. Sakowicz, M. Bralewska, T. Pietrucha, D.E. Habrowska-Górczyńska, A.W. Piastowska-Ciesielska, A. Gach, M. Rybak-Krzyszkowska, P.J. Witas, H. Huras, M. Grzesiak, L. Biesiada, Canonical, Non-Canonical and Atypical Pathways of Nuclear Factor кb Activation in Preeclampsia, Int J. Mol. Sci. 21 (2020) 5574.

[46] M.W. Socha, B. Malinowski, O. Puk, M. Wartęga, M. Stankiewicz, A. Kazdepka-Ziemińska, M. Wiciński, The Role of NF-κB in Uterine Spiral Arteries Remodeling, Insight into the Cornerstone of Preeclampsia, Int J. Mol. Sci. 22 (2021).

[47] K. Wenzel, A. Rajakumar, H. Haase, N. Geusens, N. Hubner, H. Schulz, J. Brewer, L. Roberts, C.A. Hubel, F. Herse, L. Hering, F. Qadri, C. Lindschau, G. Wallukat, R. Pijnenborg, H. Heidecke, G. Riemekasten, F.C. Luft, D.N. Muller, B. Lamarca, R. Dechend, Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats, Hypertension 58 (2011) 77-84.

[48] K. Wenzel, F. Herse, A. Rajakumar, H. Haase, C.A. Hubel, G. Wallukat, R. Pijnenborg, D.N. Muller, B.B. LaMarca, R. Dechend, PP085. Angiotensin II type 1 receptor antibodies increase angiotensin II sensitivity in pregnant rats, Pregnancy Hypertens. 2 (2012) 286-287.

[49] B. LaMarca, M. Parrish, L.F. Ray, S.R. Murphy, L. Roberts, P. Glover, G. Wallukat, K. Wenzel, K. Cockrell, J.N. Martin, Jr, M.J. Ryan, R. Dechend, Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1, Hypertension 54 (2009) 905-909.

[50] Y. Xia, R.E. Kellems, Is preeclampsia an autoimmune disease, Clin. Immunol. 133 (2009) 1-12.

[51] V.D. Garovic, W.M. White, L. Vaughan, M. Saiki, S. Parashuram, O. Garcia-Valencia, T.L. Weissgerber, N. Milic, A. Weaver, M.M. Mielke, Incidence and Long- Term Outcomes of Hypertensive Disorders of Pregnancy, J. Am. Coll. Cardiol. 75 (2020) 2323-2334.

[52] D.L. Rolnik, K.H. Nicolaides, L.C. Poon, Prevention of preeclampsia with aspirin, Am. J. Obstet. Gynecol. 226 (2022) S1108-S1119.

[53] S. Roberge, E. Bujold, K.H. Nicolaides, Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis, Am. J. Obstet. Gynecol. 218 (2018) 287-293.e1.

[54] A. Atallah, E. Lecarpentier, F. Goffinet, M. Doret-Dion, P. Gaucherand, V. Tsatsaris, Aspirin for Prevention of Preeclampsia, Drugs 77 (2017) 1819-1831.

[55] E. Richards, V. Giorgione, O. Stevens, B. Thilaganathan, Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis, Am. J. Obstet. Gynecol. 228 (2023) 395-408.

[56] M. Mendoza, E. Bonacina, P. Garcia-Manau, M. López, S. Caamiña, À. Vives, E. Lopez-Quesada, M. Ricart, A. Maroto, L. de Mingo, E. Pintado, R. Ferrer-Costa, L. Martin, A. Rodríguez-Zurita, E. Garcia, M. Pallarols, L. Vidal-Sagnier, M. Teixidor, C. Orizales-Lago, A. Pérez-Gomez, V. Ocaña, L. Puerto, P. Millán, M. Alsius, S. Diaz, N. Maiz, E. Carreras, A. Suy, Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial, JAMA 329 (2023) 542-550.

[57] L. Lin, J. Huai, B. Li, Y. Zhu, J. Juan, M. Zhang, S. Cui, X. Zhao, Y. Ma, Y. Zhao, Y. Mi, H. Ding, D. Chen, W. Zhang, H. Qi, X. Li, G. Li, J. Chen, H. Zhang, M. Yu, X. Sun, H. Yang, A randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in women at high risk in China, Am. J. Obstet. Gynecol. 226 (2022) 251. e1-251.e12.

[58] D.L. Rolnik, D. Wright, L.C. Poon, N. O'Gorman, A. Syngelaki, C. de Paco Matallana, R. Akolekar, S. Cicero, D. Janga, M. Singh, F.S. Molina, N. Persico, J.C. Jani, W. Plasencia, G. Papaioannou, K. Tenenbaum-Gavish, H. Meiri, S. Gizurarson, K. Maclagan, K.H. Nicolaides, Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia, N. Engl. J. Med 377 (2017) 613-622.

[59] C. Diguisto, A. Le Gouge, M.S. Marchand, P. Megier, Y. Ville, G. Haddad, N. Winer, C. Arthuis, M. Doret, V.H. Debarge, A. Flandrin, H.L. Delmas, D. Gallot, P. Mares, C. Vayssiere, L. Sentilhes, M.T. Cheve, A. Paumier, L. Durin, B. Schaub, V. Equy, B. Giraudeau, Perrotin F. Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo- controlled trial, PLoS One 17 (2022) e0275129.

[60] Q. Zuo, Y. Zou, S. Huang, T. Wang, Y. Xu, T. Zhang, M. Zhang, Z. Ge, Z. Jiang,Aspirin reduces sFlt-1-mediated apoptosis of trophoblast cells in preeclampsia, Mol. Hum. Reprod. 27 (2021) gaaa089 [pii].

[61] K. Mayer-Pickel, V. Kolovetsiou-Kreiner, C. Stern, J. Münzker, K. Eberhard, S. Trajanoski, I.C. Lakovschek, D. Ulrich, B. Csapo, U. Lang, B. Obermayer-Pietsch, M. Cervar-Zivkovic, Effect of Low-Dose Aspirin on Soluble FMS-Like Tyrosine Kinase 1/Placental Growth Factor (sFlt-1/PlGF Ratio) in Pregnancies at High Risk for the Development of Preeclampsia, J. Clin. Med 8 (2019) 1429.

[62] K. Navaratnam, P. Abreu, H. Clarke, A. Jorgensen, A. Alfirevic, Z. Alfirevic, Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS- like tyrosine kinase 1 (sFlt-1) /PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin, J. Matern Fetal Neonatal Med 32 (2019) 179-187.